Immunotherapy duo aims to boost cervical cancer treatment before chemoradiation
NCT ID NCT07613567
First seen May 31, 2026 · Last updated Jun 11, 2026 · Updated 3 times
Summary
This study tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to chemotherapy before standard chemoradiation can help people with locally advanced cervical cancer live longer without the disease getting worse. About 486 adults aged 18-75 with stage III-IVA cervical cancer will be enrolled. The approach combines neoadjuvant immunotherapy and chemo, followed by immunotherapy with radiation, compared to standard chemoradiation alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CERVICAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350014, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.